Is thrombin receptor protease-activated receptor 4 a key regulator of exaggerated intimal thickening in diabetes mellitus?
PAR-4 appears to play a hitherto unsuspected role in diabetic vasculopathy. The development of PAR-4 inhibitors might serve to limit mainly proliferative processes in restenosis-prone diabetic patients, particularly those patients in whom severe bleeding attributed to selective PAR-1 blockade or complete thrombin inhibition must be avoided or those who do not require anticoagulation.
Our findings demonstrate a reduction of shell deformation over time and suggest, under physiologic loading, early component deformation varies with design.